CIITA sirna

CIITA siRNA (Human)

Cat. Num. AAA8213936

• Gene Names: CIITA; C2TA; NLRA; MHC2TA; CIITAIV
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: CIITA; CIITA siRNA (Human); MHC2TA; MHC class II transactivator; CIITA sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: CIITA siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 1130

• Applicable Applications for CIITA sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human CIITA gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for CIITA sirna

siRNA to inhibit CIITA expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 156938336
• NCBI GeneID: 4261
• NCBI Accession #: NP_000237.2
• NCBI GenBank Nucleotide #: NM_000246.3
• UniProt Accession #: P33076; Q29675; Q8SNB8; Q96KL4; A0N0N9; D3DUG0; E9PFE0
• Molecular Weight: 101,661 Da
• NCBI Official Full Name: MHC class II transactivator isoform 2
• NCBI Official Synonym Full Names: class II, major histocompatibility complex, transactivator
• NCBI Official Symbol: CIITA
• NCBI Official Synonym Symbols: C2TA; NLRA; MHC2TA; CIITAIV
• NCBI Protein Information: MHC class II transactivator
• UniProt Protein Name: MHC class II transactivator
• Protein Family: MHC class II transactivator
• UniProt Gene Name: CIITA
• UniProt Synonym Gene Names: MHC2TA; CIITA
• UniProt Entry Name: C2TA_HUMAN

NCBI Description

This gene encodes a protein with an acidic transcriptional activation domain, 4 LRRs (leucine-rich repeats) and a GTP binding domain. The protein is located in the nucleus and acts as a positive regulator of class II major histocompatibility complex gene transcription, and is referred to as the "master control factor" for the expression of these genes. The protein also binds GTP and uses GTP binding to facilitate its own transport into the nucleus. Once in the nucleus it does not bind DNA but rather uses an intrinsic acetyltransferase (AT) activity to act in a coactivator-like fashion. Mutations in this gene have been associated with bare lymphocyte syndrome type II (also known as hereditary MHC class II deficiency or HLA class II-deficient combined immunodeficiency), increased susceptibility to rheumatoid arthritis, multiple sclerosis, and possibly myocardial infarction. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Nov 2013]

Uniprot Description

CIITA: a non-DNA binding transactivator that functions both in constitutive and inducible MHC Class II expression. Defects are a cause of bare lymphocyte syndrome type II (BLS II), a form of severe combined immunodeficiency disease (SCID) characterized by a profound defect in constitutive and interferon-gamma induced MHC II expression, an absence of cellular and humoral T-cell response to antigen challenge, hypogammaglobulinemia and impaired antibody production.

Protein type: Transcription, coactivator/corepressor; DNA-binding; EC 2.7.11.1

Chromosomal Location of Human Ortholog: 16p13

Cellular Component: nucleoplasm; PML body

Molecular Function: protein C-terminus binding; protein binding; transcription activator binding; DNA binding; GTP binding; transcription coactivator activity; transferase activity, transferring acyl groups; protein complex binding; kinase activity; ATP binding

Biological Process: response to antibiotic; transcription, DNA-dependent; cytokine and chemokine mediated signaling pathway; positive regulation of transcription, DNA-dependent; positive regulation of MHC class II biosynthetic process; negative regulation of collagen biosynthetic process; positive regulation of transcription from RNA polymerase II promoter; immune response; positive regulation of MHC class I biosynthetic process; negative regulation of transcription from RNA polymerase II promoter; negative regulation of transcription, DNA-dependent; phosphorylation

Disease: Rheumatoid Arthritis; Bare Lymphocyte Syndrome, Type Ii